Blumeria graminis
Blumeria graminis is a fungal pathogen that affects cereal crops, particularly barley and wheat. It is the causative agent of powdery mildew, a common disease of these crops.
Taxonomy
The species was first described by Swiss botanist Heinrich Anton de Bary in 1879. It belongs to the Erysiphales order of fungi, which are characterized by their powdery appearance. The genus Blumeria is named after German botanist Robert Hartig, who made significant contributions to the study of fungal diseases in plants.
Life Cycle
The life cycle of Blumeria graminis involves both sexual and asexual reproduction. The fungus overwinters as ascospores, which are released in the spring to infect new hosts. During the growing season, the fungus reproduces asexually through the production of conidia, which are spread by wind to infect other plants.
Disease Symptoms
Infected plants exhibit white, powdery patches on the leaves, stems, and heads. As the disease progresses, these patches darken and the plant may become stunted or die. Yield losses can be significant, particularly in years with high humidity and moderate temperatures, which favor the growth and spread of the fungus.
Management
Management of Blumeria graminis involves a combination of cultural practices, resistant varieties, and fungicides. Cultural practices include crop rotation and the removal of infected plant debris to reduce the amount of inoculum in the field. Resistant varieties have been developed through traditional breeding and genetic engineering. Fungicides are used to control the disease, but resistance to these chemicals is a growing concern.
Impact
Blumeria graminis is a major threat to cereal production worldwide. It is estimated to cause losses of up to 20% in wheat and barley crops each year. The economic impact of these losses is significant, affecting farmers' incomes and food security.
See Also
References
<references />
| This article is a stub. You can help WikiMD by registering to expand it. |
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

